The earnings call reflects a positive sentiment overall, with significant progress in clinical trials, strategic leadership appointments, and a strong financial position. However, restructuring costs and uncertainties related to the SpinCo separation present challenges.

Company Guidance

During the Galapagos Q1 2025 financial results call, the company provided comprehensive guidance and updates on its strategic initiatives and financial performance. Galapagos reported Q1 net revenues of EUR 75 million, comprising EUR 14 million from supply revenues related to Jyseleca and EUR 61 million from collaboration revenues. The company's cash balance stood at EUR 3.3 billion, with a planned cash runway extending to 2028. Galapagos detailed its innovative cell therapy pipeline, highlighting the ATALANTA-1 study, which evaluated GLPG5101, a CD19 CAR-T candidate, in eight hematological malignancies. The pivotal development for Mantle Cell Lymphoma (MCL) is slated to start in 2026, with anticipated approval in 2028. The company is focused on expanding its decentralized manufacturing units (DMUs) across the U.S. and Europe, improving the logistics and cost-effectiveness of its cell therapies. Additionally, Galapagos announced the appointment of Henry Gosebruch as the CEO of SpinCo, marking a significant step in its strategic separation plan. After the separation, SpinCo will have EUR 2.45 billion for transformative transactions, while Galapagos will retain EUR 500 million to accelerate its cell therapy pipeline. The company remains committed to advancing its R&D efforts, with a focus on oncology, immunology, and virology, and expects multiple value-driving catalysts throughout 2025.

Progress in Clinical Pipeline

Dosed first U.S. patient in the ATALANTA-1 study of GLPG5101, completed enrollment of the indolent NHL cohort, and added new cohorts. Selected MCL as a lead indication for a pivotal trial.

Innovative Manufacturing Platform

Expanded decentralized manufacturing network in the U.S. and Europe. Collaborated with AdaptImmune on developing uza-cel for solid tumors.

Financial Position

Reported a cash balance of EUR 3.3 billion at the end of Q1 2025, with plans for SpinCo to have approximately EUR 2.45 billion post-separation.

Positive Clinical Data

Achieved high overall response and complete response rates in patients receiving CD19 CAR-T cell therapy for various lymphomas with a promising safety profile.

Leadership and Strategic Developments

Announced the appointment of Henry Gosebruch as the Founding CEO of SpinCo and detailed plans for the strategic separation of SpinCo.

Galapagos (GLPG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GLPG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.35 / -	-0.803	―	―	―
Jul 23, 2025	2025 (Q2)	-0.23 / -1.85	0.078	-2475.64% (-1.93)	―	―
Apr 23, 2025	2025 (Q1)	-0.14 / -2.67	0.388	-788.92% (-3.06)	―
Feb 12, 2025	2024 (Q4)	-0.55 / 0.30	2.586	-88.32% (-2.28)
Oct 30, 2024	2024 (Q3)	-0.17 / -0.80	0.419	-291.65% (-1.22)
Aug 01, 2024	2024 (Q2)	-0.07 / 0.08	0.088	-11.36% (>-0.01)
May 02, 2024	2024 (Q1)	-0.08 / 0.39	0.385	0.78% (<+0.01)
Feb 22, 2024	2023 (Q4)	-2.14 / 2.59	-3.321	177.87% (+5.91)
Nov 02, 2023	2023 (Q3)	-1.13 / 0.42	0.327	28.13% (+0.09)
Aug 03, 2023	2023 (Q2)	-0.82 / 0.09	-0.295	129.83% (+0.38)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GLPG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 23, 2025	$33.29	$30.85	-7.33%
Apr 23, 2025	$25.50	$26.49	+3.88%
Feb 12, 2025	$24.97	$25.49	+2.08%
Oct 30, 2024	$28.59	$26.44	-7.52%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Galapagos (GLPG) report earnings?

Galapagos (GLPG) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Galapagos (GLPG) earnings time?

Galapagos (GLPG) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GLPG EPS forecast?

GLPG EPS forecast for the fiscal quarter 2025 (Q3) is -0.35.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing